Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib

Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib

Abstract Adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) associated with endocrine therapy reduced the risk of relapse for HR+/HER2− early breast cancer (eBC) patients in the monarchE and NATALEE trials. In this population-based study, we assess the real-life proportion, and long-term progno...

Full description

Saved in:
Bibliographic Details
Main Authors: Sylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, Manon Reda, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Henri Talucier, Clementine Jankowski, Charles Coutant, Laurent Arnould, Sandrine Dabakuyo
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00726-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41523-025-00726-x

Similar Items